Background: The persistence of protection from meningococcal disease following immunization with serogroup C meningococcal (MenC) glycoconjugate vaccines in infancy is short-lived. The duration of protective immunity afforded by these vaccines in other at-risk age groups (i.e., adolescents and young adults) is not known. We evaluated the persistence of bactericidal antibodies following immunization with a MenC glycoconjugate vaccine (MenCV) in adolescents and the kinetics of immune response to a meningococcal AC plain polysaccharide vaccine (MenPS) challenge or a repeat dose of MenCV.
Methods: We conducted a randomized comparative trial of 274 healthy 13-15-year-olds from whom a total of 4 blood samples were obtained (prior to administration of a dose of MenPS or MenCV, again on 2 further occasions at varying times from days 2-7 after vaccination, and finally on day 28 after vaccination. The correlate of protection was a serum bactericidal assay titer > or = 8 (with a serum bactericidal assay using human complement).
Results: A serum bactericidal assay using human complement titer > or = 8 was observed in 75% of participants at baseline (mean age, 14.5 years; mean time since routine MenCV vaccination, 3.7 years). No increase in serum bactericidal assay geometric mean titers was detected until day 5 after administration of MenPS. Geometric mean titers following administration of MenCV were significantly higher than those observed following administration of MenPS, at days 5, 7, and 28.
Conclusions: This study showed sustained levels of bactericidal antibodies for at least 3 years after immunization of adolescents with MenCV. After challenge of immunized adolescents with MenPS, there was no increase in serum bactericidal assay observed until day 5 after vaccination, indicating that immunological memory may be too slow to generate protection against this potentially rapidly invasive organism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1086/508776 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix Vaccine When Given to Healthy Infants at 3 and 12 Months of Age.
Infect Dis Ther
January 2025
Vaccine Research and Development, Pfizer R&D UK Ltd, Marlow, UK.
Introduction: Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) in infants were evaluated.
Methods: In this phase 3b, open-label, single-arm study, healthy 3-month-old infants received a single Nimenrix dose followed by a booster at age 12 months (1 + 1 series).
Unlabelled: The complement cascade is a front-line defense against pathogens. Complement activation generates the membrane attack complex (MAC), a 10-11 nm diameter pore formed by complement proteins C5b through C8 and polymerized C9. The MAC embeds within the outer membrane of Gram-negative bacteria and displays bactericidal activity.
View Article and Find Full Text PDFChinese yam polysaccharide induces the differentiation and natural antibody secretion of IgM B cells to prevent Aeromonas hydrophila infection in grass carp.
Int J Biol Macromol
January 2025
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Engineering Research Center of Green Development for Conventional Aquatic Biological Industry in the Yangtze River Economic Belt, Ministry of Education, College of Fisheries, Huazhong Agricultural University, Wuhan, China; Shenzhen Institute of Nutrition and Health, Huazhong Agricultural University, Wuhan, China; Shenzhen Branch, Guangdong Laboratory for Lingnan Modern Agriculture, Genome Analysis Laboratory of the Ministry of Agriculture, Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen, China. Electronic address:
Chinese yam polysaccharide (CYP) is an effective immunostimulant, however, its efficacy in grass carp, an important commercial fish species in Asia, remains untested. Here, our study evaluated the immunostimulatory effects of CYP on IgM B cells in vitro and on humoral immunity and immune defense against Aeromonas hydrophila infection in vivo. In vitro stimulation experiments showed that CYP could induce the secretion of IgM antibodies, because it could stimulate the proliferation and differentiation of head kidney IgM B cells.
View Article and Find Full Text PDFInjectable, Biodegradable and Photothermal Hydrogel with Quorum Sensing Inhibitory Effects for Subcutaneous Fungal Infection Treatment.
ACS Appl Mater Interfaces
January 2025
Jiangsu Engineering Laboratory of Novel Functional Polymeric Materials, Jiangsu Key Laboratory of Advanced Negative Carbon Technologies, Suzhou Key Laboratory of Soft Material and New Energy, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China.
Owing to the high invasion depth and easy formation of biofilms, the treatment of subcutaneous fungal infection is intractable and challenging. Herein, we report an injectable and biodegradable hydrogel with bactericidal, quorum sensing inhibition and antioxidant activities for the in situ treatment of subcutaneous fungal infection. The hydrogel (BEPE) was constructed by irradiating mixed bovine serum albumin (BSA), ε-polylysine and epigallocatechin gallate (EGCG)-loaded mesoporous polydopamine (PDA) under near-infrared (NIR) light.
View Article and Find Full Text PDFSerum bactericidal activity against meningococcus in patients with systemic lupus erythematosus.
Clin Exp Pediatr
January 2025
Department of Pediatrics, Hallym University Sacred Heart Hospital, Anyang, Korea.
Background: Patients with systemic lupus erythematosus (SLE) are susceptible to infectious diseases owing to various immunosuppressive treatments and disease characteristics. Meningococcal infections progress rapidly with a high incidence of severe complications and mortality; therefore, meningococcal vaccination is needed. However, there is limited evidence regarding the immunity and immunogenicity of patients with SLE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!